# Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/questions-and-answers-on-biosimilar-development-and-the-bpci-act-guidance-for-industry-guidance-for-industry/37eb8581-8678-45a9-bb8d-7e8754cae01a

> FDA guidance document: Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry:  Guidance for Industry. Issue date: September 17, 2021. Get complete insights and analysis.

---

## Details

- Title: Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2021-09-17
- Last Changed: 2021-09-17
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2011-D-0611">FDA-2011-D-0611</a>

## Related Documents

- [The “Deemed to be a License” Provision of the BPCI Act: Questions and Answers :  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/the-deemed-to-be-a-license-provision-of-the-bpci-act-questions-and-answers-guidance-for-industry/fdd76b2b-bf3b-4f6d-9988-59d75e496a17)
- [Field Alert Report Submission: Questions and Answers Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/field-alert-report-submission-questions-and-answers-guidance-for-industry-guidance-for-industry/b554a2c6-8278-4f9a-a91c-72bcdd411715)
- [S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers](https://www.globalkeysolutions.net/guidances/guidance-document/s9-nonclinical-evaluation-for-anticancer-pharmaceuticals-questions-and-answers/5b838cf4-2c2e-4c10-8a24-439ce4ce61f1)